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SAMMANFATTNING 
RECK genen är en relativt nyupptäckt gen som blivit högintressant inom cancerforskningen. 
Det är främst inom den humana medicinen som genen studerats för att eventuellt kunna 
registrera cancerns invasiva egenskaper. Uppreglerad RECK innebär ofta en avsevärt förlängd 
livstid hos patienter med allvarliga former av elakartad cancer 
 
Normalt uttrycks RECK i alla kroppens celler och har då en viktig roll i balansen mellan 
nedbrytande och uppbyggande funktioner av extracellulära matrix (ECM). RECK-proteinet är 
ett membranbundet glykoprotein som inhiberar matrix metalloproteinaser vilka har till uppgift 
att bryta ner ECM. Man har också hittat ett samband mellan RECK-genens uttryck och 
nybildning av kärl, närmare bestämt via VEGF som är en viktig och kraftig stimulant av 
angiogenes. Nedregleringen av RECK orsakas av Ras-onkogenen som annars också är en 
vanlig orsak till tumörutveckling i tidigt skede.  
  
För att en tumör skall utvecklas och få egenskaper som klassificerar den som malign, blir 
nedbrytning av ECM och mobilisering nya blodkärl steg på vägen. Om tumören hindras i 
dessa funktioner kommer den inte kunna utvecklas och växa som den vill, därför ser man 
RECK som en potentiell hämmare men även som en markör för att tidigt kunna bedöma den  
enskilda tumörens biogena malignitet och därmed hur sjukdomsförloppet för en cancerpatient 
blir.  
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SUMMARY 
The RECK gene is a relatively new discovered gene with important implications for cancer 
research. The research has been primarily concentrated on the human gene with the ultimate 
aim to identify the invasive characteristics. Up regulated RECK is linked to significantly 
prolonged survival rates in patients with severe forms of malignancies. 
 
RECK is normally expressed in all cells of the body and has an important role in the balance 
between destructive and constructive features of the extracellular matrix. The RECK protein 
is a membrane-bound glycoprotein that inhibit matrix metalloproteinases which has the 
function of breaking down the ECM. There is a significant correlation between RECK gene 
expression and the formation of new vessels, presumably via the mediation of VEGF which is 
an important and powerful inducer of angiogenesis. Research has shown that the 
downregulation of RECK is caused by the Ras oncogene, which otherwise also is a common 
cause of tumor development in the early stage. 
 
For a tumor to progress and gain characteristics that classifies it as malignant, the degradation 
of ECM and mobilization of new blood vessels are essential functions. If the tumor is 
inhibited with respect to these functions the tumor will cease to grow. RECK is therefore a 
potential inhibitor but also a prognostic marker available at early clinical stages.   
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INTRODUCTION 
The behavior of normal cells is regulated by a variety of signals. Broadly speaking signals can 
be either external or internal. However when an external signal gets in contact with the cell, 
the transcription of genes that encodes proteins necessary for the intracellular mediation of the 
specific message is elicited. The activation of such early genes may eventually result in a 
biological response such as proliferation, differentiation, locomotion or even cell death. Every 
normal cell is under tight control which basically lays down the principles for its behavior. 
However, when a cell becomes transformed, the cell ceases to respond to these regulatory 
signals. This is mainly because that genes responsible for growth inhibition or to take the cell 
into apoptosis, does not operate in accordance with control procedures. Early genes can either 
be up regulated or down regulated and then result in dysfunction leading to overexpression or 
silencing of other regulatory genes. Gene silencing is often the result of altered DNA-
methylation, i.e. when a methyl group is connected to a CG base motif and thereby creating a 
non-readable frame. Up regulation can be the result of an increased signal from another gene 
or a neighboring cell affecting the activity of a particular gene promoter. When these 
unwarranted mishaps occur, transformed cells can grow and divide in an uncontrolled 
manner, invading normal tissue and leading to metastasis throughout the body. 
 
Recently the RECK gene has been highlighted because of its correlation with metastasis and 
invasiveness. The RECK protein is a membrane-anchored glycoprotein which is present in all 
mammalian cells. The protein has its main function in tissue remodeling and thereby 
controlling the activity of remodeling enzymes as e.g. matrix metalloproteinases (MMPs), 
especially MMP-9. This quality is important in, for example wound healing and other 
physiological features.  
 
It was discovered that the level of RECK expression was correlated with the biological 
phenotype of different cancer types. RECK was found to be down regulated in tumors which 
were invasive and metastatic. Several tumors has been tested for their RECK expression 
levels and there has been a clear correlation between RECK expression and the biological 
malignancy of  liver-, pancreas-, breast-, melanoma-, fibrosarcoma-, colon- and lung 
tissue.  RECK acts as a suppressor gene which inhibits angiogenesis, invasion and metastasis. 
However, multivariate analysis showed that the methylation status of the RECK gene was the 
only independent prognostic factor affecting overall survival of cancer patients (p = 0.037). 
This suggests that RECK is a promising biomarker in the early detection of cancer. (Long et 
al., 2008)  
 
MATERIAL AND METHODS 
This is a literature study where the main material is referred to the webpage pubmed.com. The 
search was mainly correlated to words such as “RECK”, “tumor”, “matrix metalloproteinases 
”,“ MMP ”,“ angiogenesis ”,“ metastasis ”,“ gene expression ”,“ cancer” and “VEGF”.  
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LITTERATURE REVIEW 
 
Gene structure 
RECK is named after its structural features and its activity, Reversion-inducing Cysteine-rich 
protein with Kazal motifs. (Takahashi et al., 1998) Kazal-like serine protease inhibitors are 
defined by a conserved sequence motif. A typical Kazal domain contains six cysteine residues 
leading to three disulphide bonds with a 1-5/2-4/3-6 pattern. Most Kazal domains described 
so far belong to this class (Tian and Kamoun, 2005).  The RECK gene was initially isolated as 
a suppressor gene encoding a novel membrane-anchored glycoprotein and was later found to 
suppress tumor invasion and metastasis by regulating matrix metalloproteinase-9. Its 
expression is ubiquitous in normal tissues, but undetectable in many tumor cell lines and in 
fibroblastic lines transformed by various oncogenes. The human RECK gene is located 
on chromosome region 9p13->p12 (Takahashi et al., 1998).  The assignment to this 
chromosomal region is particularly illuminating since several potential tumor suppressor 
genes are located on chromosome 9. Most importantly, among these is the p16INK4a 
which plays a particularly distinct role in melanoma. (Clark et al., 2007)  
 
The human RECK gene spans over a 87 kb region and contains 21 exons and 20 introns with 
13 single nucleotide polymorphisms (SNPs). Four SNPs were identified in the coding region 
of the gene (exons 1, 9, 13 and 15), and the remaining nine in introns 5, 8, 10, 12, 15 and 
17. Within the coding sequence lie four of these SNPs which increase the opportunity of 
disease implication.  Polymorphisms lead to morbid function in the RECK protein 
structure (Clark et al., 2007) There is a highly homologous murine counterpart located on 
mouse chromosome 4 that consists of 19 exons and 18 introns. However, the RECK gene 
appears to be conserved throughout development. Recently, a mature cDNA clone from 
Xenopus laevis of the RECK gene was generated. RECK expression appeared to be low 
during gastrulation but increased during neurolation and into organogenesis. Furthermore, 
RECK was localized to the anterior and dorsal sides of the developing embryo. (Willson, 
2012) 
 
The RECK gene is also conserved in chimpanzee, Rhesus monkey, cow, rat, chicken, fruit fly, 
and mosquito. (NCBI, 2014) 
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Fig. 1 Comparison of amino acids between canine, mouse and human, of the RECK sequence. Identical 
aminoacids are in boxes. (Takagi et al., 2005) 
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Fig. 2 The general structure of the RECK protein. Adapted from  Takahashi et al., 1998 
 
Protein structure 
The RECK protein consists of 971 amino acids and according to Takahashi et al., 1998 shows 
that both the human and mouse cDNA share 93.0% identity with each other. The protein is 
cysteine rich (9%) and it includes hydrophobic regions in both ends, NH2-terminal and 
COOH-terminal. The NH2-terminal acts as a signal peptide while the COOH-terminal 
operates as a signal for glycosylphosphatidylinositol (GPI) anchoring. At the center of the 
RECK protein there are three serineprotease inhibitor-like (SPI) domains. The initial parts of 
the middle domain correspond to the Kazal motif while the second and third do not. 
(Takahashi et al., 1998) These SPIs are believed to inhibit the protease activity, either by 
physical ‘trapping’ or by ‘reversible tight binding’. SPI;s most probably play an important 
role in the inhibition of MMP. (Clark et al., 2007) Also there are two regions with epidermal 
growth factor (EGF)-like repeats in the middle domain space of the protein. RECK is named 
after these structural features and its activity, Reversion-inducing Cysteine-rich protein with 
Kazal motifs. (Takahashi et al., 1998)  
 
One site is located in the first third of the protein sequence; this is marked by five cysteine 
repeats which have a particular functional value and as well containing several glycosylation 
sites at asparagine (Asn) residues. These sites are essential for obtaining proper interaction 
with MMP-9 and MMP-2 which is the core function of the RECK protein. (Clark et al., 2007)  
 
The RECK COOH-terminal hydrophobic region and GPI interaction are both anchored to the 
cell membrane. The fact that RECK is membrane-anchored is probably essential for 
intracellular signal transduction  
 
  
 
 
Physiological role of RECK 
The primary function of RECK is to serve as an important mediator of tissue remodeling. 
RECK inhibits matrix metalloproteinase (MMP-2 and MMP-9) and MT1-MMP post-
transcriptionally. MMP-2 and MMP-9 break down extra-cellular matrix (ECM) both under 
normal conditions and during pathological conditions. Normally RECK is expressed in all 
human and mammalian organ cells including mesenchymal tissues and in vascular smooth 
muscle cells. (Oh et al., 2001)  
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In a study by Takahashi et al., 1998 it was confirmed that activated Ras-oncogenes suppress 
the RECK promoter. Down-regulation of RECK mRNA was also induced by a variety  
of other oncogenes, such as v-fos, c-myc, v-src, v-fms, v-fes and v-mos. (Takahashi et al., 
1998) Dramatic morphological alternations developed as a result of mutated Ras-genes, which 
occurs often in many kinds of tumors.  (Sasahara et al., 1999) 
 
 Oh et al., 2001 created KO-mice with a 
disrupted RECK gene in order to understand the 
physiological significance. Embryos of RECK
-
/
-
 
mice were much smaller in body size, had a 
reduction in structural integrity and frequent 
abdominal hemorrhage. A histological analysis 
also revealed severe disorganization of 
mesenchymal tissues and terminated 
organogenesis in the mutant embryo mice. 
Moreover, vascular endothelial cells did not form 
tight and thin tubular structures as seen in the 
wild-type embryos, but rather displayed 
primitive vascular plexuses which suggest a 
deficient blood maturation and not 
vasculogenesis. 
 
 
The physiological role of RECK in animal 
experiments 
To be able to understand the main functions of 
RECK there has been several studies made in 
vivo. (Oh et al., 2001) (Namwat et al., 2010) 
Mice with a defective RECK gene have been 
studied. Heterozygous mice, with a RECK 
mutation (RECK
-/+
) were healthy and fertile, but 
they did not give birth to any homozygous 
offspring (RECK 
-/-
). A ratio, about 1:2 of wild 
type to heterozygous offspring indicated a 
recessive lethal phenotype. Thus, embryos were 
examined from heterozygous intercrosses at 
different developmental stages. No obvious 
phenotype was seen in RECK
-/-
 embryos in early 
stage. However two-thirds of the embryos died 
due to the lack of heartbeat. Later in embryonic 
development none of the RECK 
-
/
-
 embryos 
survived. These embryos differ from embryos 
with a functional RECK since they have smaller 
body size, a prominent reduction in structural 
integrity and recurring abdominal hemorrhage. This was revealed by histological examination 
of the mutant embryos where the results displayed a severe disarray of mesenchymal tissues 
and disrupted organogenesis. However, most importantly the vascular endothelial cells did 
not form tight and tubular structures as they ought to. The vascular network that developed in 
the yolk sac resembled primitive vascular plexuses, which suggests defects in blood vessel 
maturation, rather than vasculogenesis. (Oh et al., 2001) The difference in vasculogenesis and 
RECK expression 
Organ    
Heart   (-) 
Brain   - 
Placenta  +  
Lung ++   
Liver   (-) 
Skeletal 
muscle 
 +  
Kidney  +  
Pancreas   - 
Spleen  +  
Thymus  +  
Prostate  +  
Testis ++   
Ovary ++   
Small intestine ++   
Colon mucosa ++   
Leukocyte   (-) 
Table. 1.  
Detection of RECK mRNA in human organs, 
done by Northern blot hybridization. Adapted 
from Takahashi et al., 1998 
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angiogenesis will be discussed later on.  
 
A study on Syrian golden hamsters was performed by Namwat et al., 2010, where the 
hamsters were divided into two groups. Group 1 remained untreated and group 2 was infected 
with virus to develop cholangiocarcinoma. Liver tissue was frequently examined with 
immunohistochemical staining for RECK, MMP-2 and MMP-9. The results of the control 
group implied that the expression of RECK was high but there was no sign of MMP-2 or 
MMP-9 expression. In group two, RECK expression was less intense when precancerous 
lesions had started to develop. When the cholangiocarcinoma was manifest, no RECK 
staining was observed at all in cancer cells, but intense RECK expression still prevailed in 
most surrounding hepatocytes.  Positive staining of MMP-2 and MMP-9 was observed in both 
precancerous tissue and in tumor cells. (Namwat et al., 2010) 
 
Pathophysiological role of RECK 
RECK is expressed in all normal tissues in rodents as well in man. (Takahashi et al., 1998) It 
has been demonstrated in tissue samples from various invasive human cancers that the RECK 
gene is either down-regulated or not expressed above detection level. (Takeuchi et al., 2004) 
(Takenaka et al., 2004) (Masui et al., 2003) (Zhang et al., 2012) 
 
In one study, which aimed to demonstrate lack of RECK expression in invasive and metastatic 
breast cancer, significant results confirmed a decreased RECK expression as a negative 
survival factor for breast cancer. Low expression levels of RECK were correlated with the 
occurrence of lymph node metastasis. However, the results were not significantly for 
correlated with age, menopausal status or tumor size. (Zhang et al., 2012)  
 
Several other studies have also demonstrated similar results in liver, pancreas, breast, 
melanoma, fibrosarcoma, colon and lung malignancies. (Chung et al., 2012) (Zhang et al., 
2012) (Takahashi et al., 1998) (Masui et al., 2003) (Takeuchi et al., 2004) (Takenaka et al., 
2004) 
 
One of the earliest examples of RECK down regulation was how it correlated with aberrant 
activation of the Ras oncogene. This demonstrated a particularly important link to the 
intracellular mediation of mitogenic messages. The main cause of carcinogenesis is 
considered to be changes in the cellular genome that affect the expression or function of genes 
controlling cell growth and differentiation. The family of Ras genes is frequently mutated in 
human tumors. The Ras proteins resemble the G-proteins both functionally and structurally 
where they them control adenylate cyclase. This implies that normal p21ras2 proteins are 
involved in the transduction of external stimuli that induce growth or cell differentiation. 
(Bos, 1989) The connection between Ras and RECK was demonstrated by Takahashi et al., 
1998 by detecting endogenous RECK mRNA in untransformed mouse NIH 3T3 cells, which 
was down-regulated in Ras-transformed cells. When Ras is turned on, the RECK gene is 
down-regulated leading to amplified secretion of MMP-9, which contributes to the invasive 
capacity and morphological transformation of the cells. Ras signaling positively regulates 
MMP-9 through multiple mechanisms, mainly through transcriptional activation, while 
RECK acts as a negative down-regulator of MMP-9. (Takahashi et al., 1998) 
 
9 
 
Fig. 3 
Summary of RECK controls. Sp1 promoter site is affected by several different pathways and 
thereby inhibiting RECK gene. Oncogenic Ras is the primarily activator. NSAID and TSA acts 
as inhibitors, they show potential for cancer therapy by lowering RECK down regulation. The 
primary function of RECK is to inhibit ECM breakdown and angiogenesis. Adapted from Clark 
et al., 2007. 
To metastasize, a tumor needs to possess the ability to induce angiogenesis and invasiveness. 
Tumor angiogenesis implies that cancer cells are recruiting blood vessels for their survival as 
the tumor enlarges. Invasiveness is by definition a tumor which escapes from its original site 
by penetrating the basal lamina and other extracellular matrix structures. This implies that if 
these functions can be inhibited, the tumor growth will cease. Extracellular matrix supplies a 
substantial framework upon which cells grow, migrate and differentiate which is the main aim 
in the life of a tumor. Extracellular matrix (ECM) consists primarily of collagen, 
proteoglycans and glycoproteins, for instance laminin and fibronectin. During growth and 
development of the body, it’s necessary for the ECM to constant remodel, this process 
requires extracellular proteases named matrix metalloproteinases (MMPs). They are necessary 
in wound healing, osteoporosis, rheumatoid arthritis and cancer.  In addition it’s also required 
for the metastatic process of the tumor to have active MMPs for  the tumor to break through 
the basal lamina and migrate. Three types of MMPs are potentially involved in the process of 
cancer, MMP-9, MMP-2 and MT1-MMP. (Oh et al., 2001) It is known that RECK is a 
negative regulator of MMP-9 mRNA but not MMP-2 mRNA. (Takagi et al., 2009)  
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Vascular endothelial growth factor (VEGF) is a powerful inducer of angiogenesis whereas it 
can either be soluble or bound to ECM structures or cell surfaces. (Bergers et al., 2000) 
Intratumoral microvessel density (IMVD) is a measurement of tumor angiogenesis which 
closely correlates with tumor progression and prognosis in a variety of malignant tumors. 
VEGF is contributing to the IMVD value when activated. (Takenaka et al., 2004)  MMP-9 is 
among several enzymes which are able to activate VEGF in tumor tissue, so as RECK gets 
down-regulated by oncogenes; MMP-9 is up-regulated and is then able to contribute to 
angiogenesis as well. (Bergers el al., 2000) According to Takenaka et al., 2004 there is a 
significant inverse correlation between RECK and VEGF which suggests that RECK 
suppresses angiogenesis induced by VEGF. 
 
Inhibition of Matrix Metalloproteinases (MMPs) 
The family of matrix metalloproteinases (MMPs) is degradation enzymes of the extracellular 
matrix (ECM), they’re endopeptidases that depend on Ca2+, Zn2+ and neutral pH for 
activation. (Vu, 2000) The MMP family consists of >20 members and they are divided in to 
eight groups because of their shared functional domains, five of them are secreted and three 
are membrane-bound. (Egeblad and Werb, 2002) By removal of an amino-terminal 
propeptide on the MMPs they precede in an active form. Before this happens they are 
synthesized as secreted or transmembrane proenzymes. It is thought that the enzyme rests in 
latent form while the propeptide is attached in time of interaction of a cysteine residue. In the 
propeptide, the enzyme is maintained in an inactive, latent form by a specific interaction 
between cysteine and a zinc motif is the active site of the enzyme. If this interaction gets 
disrupted it will trigger a cysteine switch mechanism, which will activate the enzyme. (Vu, 
2000) The cysteine switch means that a cysteine (Cys), blocks a zinc atom of the active site 
which keeps the enzyme inactive. Conversely the dissociation of Cys from the zinc atom is 
considered as a switch that leads the enzyme to activation. (Chakraborti et al., 2003)  The 
cleavage can be induced by other MMPs or by other proteases. Alternatively they can be 
activated by chaotropic agents. Upon activation, the MMP can be inhibited by a family of 
tissue inhibitors of metalloproteinases, TIMPs, or by small molecules with TIMP-like 
domains. (Vu, 2000) TIMP 1 -2, -3 and -4 are the best studied inhibitors. They reversibly 
inhibit MMPs in a 1:1 stoichiometric fashion. They appear to be tissue-specific and differ in 
their ability to inhibit different types of MMPs. (Egeblad and Werb, 2002) However, RECK is 
the only hither to known membrane-bound inhibitor of MMPs. (Oh et al., 2001) MMPs are 
important in cancer research because of their correlation with high expression and activity of 
MMPs in almost every type of human and rodent cancer. They are also correlated with 
advanced tumor stage, increased invasion and metastasis and shortened survival. But, TIMP-1 
and -2 also have a connection with poor prognosis in cancer. High TIMP levels are equivalent 
to high levels of MMP, though the expression is flavoring the MMPs and therefore high levels 
of TIMP can be associated with unfavorable tumor progression, but not cause it. Furthermore, 
TIMPs can also up-regulate vascular endothelial growth factor (VEGF) secretion. (Egeblad 
and Werb, 2002)   
 
The tight regulation of MMP genes is important for tissue break-down and reconstruction 
balance. If overexpressed, several other pathological conditions arise as a consequence of 
connective tissue destruction. These include diseases such as arthritis and periodontitis.  
(Matrisian, 1994)  
 
It has been demonstrated that overexpression of RECK decreases the level of MMP-9 mRNA. 
In vitro, RECK/MMP-9 and RECK/MMP-2 where correlated. Overexpression of RECK 
lowered the levels of MMP-9 mRNA but the levels of MMP-2 mRNA stayed unaffected. But, 
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MMP-9 recovered when RECK expression was silenced, leaving levels of MMP-2 unaffected. 
(Takagi et al., 2009) However, when the effect of RECK expression on MMP-9 promoter 
activity was examined the promoter region was found to be located at -700 to -400 bp and the 
results acknowledged that MMP-9 promoter region is exposed by RECK-mediated 
suppression. (Takagi et al., 2009) 
 
Inhibition of tumor angiogenesis 
Cells have two ways of to recruiting new blood vessels: either angiogenesis or 
vasculogenesis. The two approaches differ and angiogenesis is the process by which new 
vessels grow from existing endothelial lined vessels. Angiogenesis is an invasive process 
which requires proteolysis of extracellular matrix, proliferation, synthesis of new matrix 
components and migration of endothelial cells. The angiogenic response is important in most 
pathological conditions as e.g. inflammation, hypoxia and wound healing. But, the process of 
recruiting blood vessels, angiogenesis, is also important during tumor growth and metastasis. 
Meanwhile, vasculogenesis implicates that endothelial cells develops by proliferation from 
existing stem cells. This requires the presence of stem cells, in particular angioblasts which 
differentiate and migrate in response to signals. This occurs during fetal development where 
angiogenesis is absent. (Stetler-Stevenson, 1999)  
 
VEGF or vascular endothelial growth factor is a family of proteins normally expressed in 
endothelial cells where they could either be freely soluble or bound to cell surfaces and ECM 
due to their heparin-binding properties. (Bergers et al., 2000) They are the main inducers of 
angiogenesis and are involved in several functions in the body such as bone formation, 
hematopoiesis, wound healing and development, i.e. every process in which angiogenesis has 
a prime role. VEGF is also produced by other cells connected to the vascular system, but it is 
also known that VEGF is produced by tumor cells. (Tammela et al., 2005) VEGF was induced 
by MMP-9 in a study on multistage pancreatic cancer. MMP-9 proved to be the only 
proteinase to increase the release of VEGF in vitro and a selective inhibitor of MMP-9 was 
the most effective blockade of the initial angiogenic switch. (Bergers et al., 2000) Along with 
this, it’s known that MMPs have more tasks than ECM breakdown to form new vessels; they 
can also promote angiogenesis by regulating endothelial cell attachment, proliferation, growth 
and migration. Later studies even show that MMP could generate or release angiogenic 
inhibitors such as angiostatin from the ECM. Tumor macrophages can secrete MMP-9 which 
can indirectly affect endothelial cell behavior by releasing proangiogenic factors and others. 
(Stetler-Stevenson, 1999) This correlation between MMP-9 and VEGF was demonstrated in 
canine lymphoma. The results were based on a comparison between B-cells and T-cells 
lymphoma in vivo by immunocytochemistry staining to specifically detect VEGF-A, which is 
the most common vascular growth factor in the VEGF-family. It was shown that high 
expression of mRNA and protein VEGF-A were detected in both B-cells and T-cells 
lymphoma. Also, the levels of VEGF-A mRNA was correlated with the levels of MMP-9. 
(Aricò et al., 2013) In canine mast cell tumors the result was similar, where the mast cells 
released high levels of VEGF-A mRNA as well as protein, equivalent to expression of MMP-
9 production. (Giantin et al., 2012) 
 
Correlation between RECK expression and tumor angiogenesis showed that they could not 
detect VEGF could not be detected in normal colorectal mucosa. However it could be 
detected in carcinoma cells, mainly in their cytoplasm or membranes. 26.4% of the specimens 
were classified as expressing high levels of VEGF and the result of an inverse correlation 
between RECK and VEGF expression was clearly significant. A significant relationship 
between RECK and microvessel density (MVD) was also found as an inverse correlation. 
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(Takeuchi et al., 2004) Microvessel density is a measure of the number of vessels per high-
power (microscope) field and reflects the intercapillary distance. The net balance between 
stimulating and inhibitory angiogenic factors which ultimately result in local formation of 
vessels in microregion affects the intercapillary distance. Similar effects could be achieved by 
non angiogenic factors including oxygen and nutrient consumption rates. (Hlatky et al., 2002) 
 
The possibility that RECK suppresses the tumor angiogenesis induced by VEGF was also 
observed in a study of non-small cell lung cancer. The results in the study presented inversely 
correlated RECK expression with IMVD and the effects of RECK where shown in tumors 
expressing VEGF in higher levels. Consequently when RECK expression was weak in the 
tumor cells, the mean IMVD increased followed by an increased VEGF-score and so in the 
other way. (Takenaka et al., 2004)  
 
Oh et al. presented data that showed limited vascularization in very large RECK expression 
tumors, to a few large blood vessels where only the cells surrounding them survived. This 
indicated that levels of high RECK expression limits the angiogenic function of the tumor 
which leads to decreased tumor growth. (Oh et al., 2001) 
 
DISCUSSION 
Down regulation of the RECK gene is directly correlated with tumor invasion, metastasis and 
angiogenesis. (Clark et al., 2007) The RECK gene is a relatively recent discovery and has 
become a central topic in the discussion of new diagnostic biomarkers detecting early stages 
of cancer and the possibility of developing prolonged survival indicators for  cancer patients. 
(Zhang et al., 2012) The RECK protein does not have a cytotoxic effect on tumor 
cells.(Takenaka et al., 2004) Expression of RECK simply inhibits the tumor growth by 
regulating extra cellular matrix breakdown and the inhibition of the formation of new blood 
vessels. When these processes are halted, the tumor is unable to break through the basal 
lamina and to spread to other places in the body. In other words, the metastatic process is 
blocked. (Oh et al., 2001) Normally the RECK protein regulates matrix metalloproteinase 
activity which is important during wound healing and for example osteoporosis. When RECK 
is acting efficiently, it is inhibiting MMPs so that the ECM breakdown is disrupted. When 
RECK is absent the breakdown of ECM is totally unopposed and this facilitates tumor growth 
and metastasis. (Takahashi et al., 1998) The RECK expression pattern is conserved in several 
species and the most important and evaluated is canine, mouse and human cell lines. The 
discovery of RECK in several species suggest that the gene has a fundamental and 
phenotypically conserved biological role. (NCBI, 2014) 
 
It is known that RECK inhibits MMPs, especially MMP-9 which is an important ECM 
dilapidator. (Takagi et al., 2009) MMP-9 does also have a close relation to another powerful 
inducer of angiogenesis, VEGF. (Aricò et al., 2013) In that way the RECK expression is 
important because it upholds a constructive as well as a destructive balance. Both VEGF and 
MMPs are important for a variety of physiological processes, not least for tissue regeneration 
and wound healing but they are also the key to our understanding of tumor invasion. (Egeblad 
and Werb, 2002) A metastatic tumor requires de novo vessel formation to be able to continue 
to grow as well as efficient ECM breakdown. If both VEGF and MMP are inhibited by RECK 
expression it implies that RECK plays a highly important and a much significant role in 
malignant cancer development.  
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There are still unsolved issues considering the role of RECK, especially the exact correlation 
between VEGF function and RECK expression. Also, even further in vivo animal studies are 
required for a better understanding of the multifunctional facets of the gene. Still, hitherto 
published studies suggest that RECK is a potential biomarker for early detection which may 
well be used for monitoring treatment in the future.  
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